Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-120 or AG-221 with induction and consolidation chemotherapy for newly diagnosed IDH-mutated acute myeloid leukemia
NL-OMON53153Phase 1Recruiting
- Sponsor
- Servier
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ivosidenib and enasidenib in acute myeloid leukemia (AML) (2 arms), sponsored by Servier. Primary endpoints: Dose-limiting toxicities, Adverse events and serious adverse events and 2 more. Started Feb 2017; status: recruiting.
02
Drugs
ivosidenibenasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON53153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53153.